Cubist reiterated at outperform by RBC

RBC Capital Markets analyst Jason Kantor reiterated Cubist Pharmaceuticals Inc. at outperform, above average risk, on news that the company's Cubicin phase 3 trial was published in the New England Journal of Medicine. The article of the trial in patients with bacteremia including endocarditis provides Cubist with an important new marketing tool in advance of two significant medical meetings for infectious disease doctors, according to the analyst. The publication follows the Food and Drug Administration approval of Cubicin for the broad indication of staph bacteremia. Shares of the Lexington, Mass.-based biopharmaceutical company were up 34 cents, or 1.56%, at $22.16 on volume of 1,547,404 shares versus the three-month running average of 1,295,350 shares. (Nasdaq: CBST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.